Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction (ONOH)

10. januar 2020 opdateret af: Daniel Forman, MD, Gladwin, Mark, MD

Nitrite Benefits to Mediate Fatigability in Older HFpEF Patients

This is a randomized double blinded controlled trial of 20-40 mg sodium nitrite tid in subjects with HFpEF. Primary outcomes are measures of physical function with non-invasive and invasive cardiopulmonary exercise testing, and fatigability, skeletal muscle bioenergetics, serology including inflammatory markers and platelet bioenergetics, quality of life measures.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Age-related physiological changes predispose to heart failure with preserved ejection fraction (HFpEF). Thus, HFpEF prevalence is escalating as the older population expands. High mortality and morbidity, diminished quality of life, and spiraling healthcare costs are typical consequences, and no effective HFpEF therapy is known. Therefore, several small exercise training (ExT) trials for HFpEF stand out by showing that ExT result in improved aerobic exercise capacity and infer that ExT constitutes novel substantive therapy. Nonetheless, such benefit was evident only after months of moderate to high intensity ExT; regimens that are unfeasible for most patients. In fact, poor compliance with ExT is typical in most HFpEF patients. The investigators propose there are intrinsic physiological components of HFpEF pathophysiology that predispose to "fatigability". The investigators advance the concept of fatigability by quantifying it as a performance-based measure; i.e., subjective tiring during a standardized steady-state walking (perceived fatigability) and deterioration of self-selected walking speed over time (performance fatigability). The investigators assert that therapies to reduce fatigability will enhance HFpEF outcomes. Ongoing studies reveal pleiotropic benefits of oral inorganic nitrite (NO2), including enhanced performance of skeletal muscle (metabolism and bioenergetics) and vasomotor responses (systemic and pulmonary). The investigators' pilot work shows safety and biological efficacy of oral NO2 capsules. Thus, the investigators propose a randomized, controlled, double-blinded trial to study oral NO2 therapy in older (≥70 years) HFpEF patients. Aim 1 explores the utility of NO2 capsules to reduce perceived and performance fatigability (rated perceived exertion), improve aerobic capacity (peak oxygen uptake) and increase daily activity (accelerometry). Aim 2 delineates the mediating processes by which NO2 benefits are achieved. Skeletal muscle determinants are differentiated from the right and left heart vasomotor dynamics by integrating assessments using 31Phosphorus magnetic resonance spectroscopy and percutaneous needle muscle biopsies with those made using non-invasive and invasive cardiopulmonary exercise testing, near infrared spectroscopy and other techniques. The principal investigator is trained geriatrics and cardiology, and is solidly oriented to the dynamics of aging and cardiovascular disease (clinically and mechanistically) with particular expertise in functional assessment and skeletal muscle gene expression as determinants of performance. The investigative team provides formidable synergies that are well-suited to this translational investigation of systemic, cellular, and sub-cellular physiological dynamics. Our proposal is significant in multiple respects: 1) HFpEF is endemic with aging and constitutes a critical contemporary healthcare challenge today's growing population of older adults. 2) Fatigability is rooted in HFpEF pathophysiology, but it has not previously been addressed as a key part of management. 3) NO2 therapy is a novel and compelling therapeutic strategy. 4) Mechanisms underlying fatigability are clarified; we advance principles of patient-centered care by clarifying mechanisms that underlie a patient's experience of fatigability.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

15

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • UPMC Montefiore Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

70 år og ældre (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥70 years

  • Diagnosis of HFpEF [adapted from the 2016 European Society of Cardiology (ESC) Guidelines to include:

    1. Prior diagnosis of HF via one of these:

  • medical record diagnosis by attending cardiologist
  • verbal confirmation of HFpEF with attending cardiologist
  • PI review of medical record to confirm HFpEF AND 2. Ejection Fraction % ≥40
  • Clinically stable (euvolemic; baseline heart rate <100 bpm) and without hospitalization or invasive cardiac procedure for 6 weeks
  • Patients using 81 milligram (mg) aspirin (ASA) will be eligible, but will be asked to hold the medication for 3 days prior to biopsy. This technique has previously been used with consistent safety. Patients will also be asked to avoid non-steroidal anti-inflammatory medications (NSAIDs) for 2 days prior to the biopsy.
  • Patients using anti-thrombin and anti-platelet therapy will plan to modify prior to muscle biopsies individually in coordination with the participant's primary cardiologist.

Exclusion Criteria:

  • Allergy to lidocaine
  • BP >180/95 or <100/60
  • Anemia: Hgb<11.0 (♂),10.0 (♀)
  • Dementia or inability to give informed consent
  • End-stage malignancy
  • Severe orthopedic exercise limitation
  • Use of chronic oral corticosteroids or other medications that affect muscle function.
  • Chronic alcohol or drug dependency.
  • Any bleeding disorder that would contraindicate biopsy such as history of clinically significant bleeding diathesis (e.g., Hemophilia A or B, Von Willebrand's Disease or congenital Factor VII deficiency).
  • Psychiatric hospitalization within the last 3 months
  • Major cardiovascular event or procedure within the prior 6 weeks
  • HF secondary to significant uncorrected primary valvular disease (except mitral regurgitation secondary to left ventricular dysfunction). If valve replacement has been performed, patient may not be enrolled for 12 months after this procedure.
  • Severe uncorrected primary valvular heart disease (if valve replacement has been performed, patients will not be eligible for at least 12 months)
  • Mechanical valve replacement requiring warfarin
  • Peripheral or pulmonary artery disease
  • Currently taking clopidogrel for a recent stent placement and/or a complex atherosclerotic lesion such that holding clopidogrel creates disproportionate risk.
  • Current use of organic nitrates or phosphodiesterase type 5 inhibitors (PDE5s)
  • Unable to hold warfarin or use bridging therapy, or to hold aspirin for 3 days (81 mg), 3 days (325 mg) prior to muscle biopsy or thienopyridine medications for 5 days prior to muscle biopsy.
  • Subjects with diabetes whose HgbA1c >10.0
  • Other chronic unstable disease such as active neoplasm, end stage chronic kidney, liver or other organ disease,

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment
20 or 40 mg sodium nitrite tid
Medicin: sodium nitrite
Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
Andre navne:
  • nitrite
Placebo komparator: Control
20 or 40 mg placebo tid
Medicin: Control
Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
Andre navne:
  • Placebo

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cardiorespiratory Fitness
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Assessment of peak Oxygen uptake (VO2) maximum via symptom limited exercise testing
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Perceived Fatigability
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Assessment of Rate of Perceived Exertion (RPE) during steady state exercise testing at the last minute of the test. The RPE scale (Rate of Perceived Exertion) goes from 6-20 with a higher number indicating more effort and possibly a worse outcome.
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Bioenergetics: In-Vivo 31P MRS Respirations
Tidsramme: Week 3 (pre drug) to week 10(post drug); approx. 8 weeks
Phosphocreatine reuptake after exercise during the kicking exercise in the 31P MRS (magnetic resonance spectroscopy)
Week 3 (pre drug) to week 10(post drug); approx. 8 weeks
Bioenergetics: Ex-Vivo Mitochondrial Respiration Analysis
Tidsramme: Week 5 (pre-drug) to week 16 (post-drug); approx. 8 weeks
Mitochondrial respiration was analyzed by assessing O2 consumption by skeletal muscle mitochondria at Energetic State 3.1 using the Oroboros instrument. This state is generally used a marker for mitochondrial efficiency. Increases in consumption are generally linked to a better outcome.
Week 5 (pre-drug) to week 16 (post-drug); approx. 8 weeks
Exercise-induced Changes in Pulmonary Arterial Pressure
Tidsramme: Week 3 (pre-drug) to week 10 (post drug); approx 8 weeks
Pulmonary arterial pressure, an indication of cardiopulmonary hemodynamics and cardiac function, was measured at rest and at peak exercise during an invasive cardiopulmonary exercise test.
Week 3 (pre-drug) to week 10 (post drug); approx 8 weeks
Exercise-induced Changes in Pulmonary Capillary Wedge Pressure
Tidsramme: Week 3 (pre-drug) to week 10 (post drug); approx 8 weeks
Pulmonary capillary wedge pressure, an indication of cardiopulmonary hemodynamics and cardiac function, was measured at rest and at peak exercise during an invasive cardiopulmonary exercise test.
Week 3 (pre-drug) to week 10 (post drug); approx 8 weeks
Patients With Pulmonary Hypertension
Tidsramme: Week 3 (pre-drug) to week 10 (post drug); approx 8 weeks
Right Ventricular-Pulmonary Artery Coupling, assessed by right ventricular ejection fraction (RVEF) and pulmonary artery systolic pressure (PASP), decreases with worsening right heart failure. We will be measuring this by assessing RVEF and PASP during invasive cardiopulmonary exercise testing in patients that meet criteria for pulmonary hypertension.
Week 3 (pre-drug) to week 10 (post drug); approx 8 weeks
Steps From Accelerometry Assessment of Daily Activity
Tidsramme: Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks
Actigraph device-specific activity steps on daily-wear wrist device based on movement.
Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks
Sedentary Events From Accelerometry Assessment of Daily Activity
Tidsramme: Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks

Assessment of daily activity using accelerometry on a daily-wear wrist device.

Sedentary bout is a triggered stint of time that the patient is not moving or has low level of activity sensed by the accelerometer.
Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks
Light Activity Duration From Accelerometry Assessment of Daily Activity
Tidsramme: Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks

Assessment of daily activity using accelerometry on a daily-wear wrist device.

Light activity is a triggered stint of time that the patient has a slightly elevated amount of activity based on biometrics such as movement and heart rate.
Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks
Moderate to Vigorous Physical Activity From Accelerometry Assessment of Daily Activity
Tidsramme: Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks

Assessment of daily activity using accelerometry on a daily-wear wrist device.

MVPA is Moderate-to-vigorous physical activity that is a triggered stint of time that the patient has a slightly elevated amount of activity based on biometrics such as movement and heart rate.
Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks
Vector Magnitude Counts From Accelerometry Assessment of Daily Activity
Tidsramme: Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks

Assessment of daily activity using accelerometry on a daily-wear wrist device.

Vector Magnitude in counts per day are accelerations in 3 dimensions that indicate activity. More counts is associated with more activity. More counts in a shorter duration of time indicate light, moderate, and vigorous activity.
Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks
Sedentary Event Duration From Accelerometry Assessment of Daily Activity
Tidsramme: Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks

Assessment of daily activity using accelerometry on a daily-wear wrist device.

Sedentary bout is a triggered stint of time that the patient is not moving or has low level of activity sensed by the accelerometer.
Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks
Light Activity Events Percentage of Day From Accelerometry Assessment of Daily Activity
Tidsramme: Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks

Assessment of daily activity using accelerometry on a daily-wear wrist device.

Light activity is a triggered stint of time that the patient has a slightly elevated amount of activity based on biometrics such as movement and heart rate.
Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks
Moderate to Vigorous Physical Activity Percentage From Accelerometry Assessment of Daily Activity
Tidsramme: Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks

Assessment of daily activity using accelerometry on a daily-wear wrist device.

MVPA is Moderate-to-vigorous physical activity that is a triggered stint of time that the patient has a slightly elevated amount of activity based on biometrics such as movement and heart rate.
Week 1(pre-drug) to week 16(post-drug); approx. 16 weeks

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Adiponectin
Tidsramme: Week 5 (pre drug) to week 16 (post drug); approx. 8 weeks
Change in adiponectin
Week 5 (pre drug) to week 16 (post drug); approx. 8 weeks
Blood Nitrate
Tidsramme: Week 5 (pre drug) to week 16 (post drug); approx. 8 week
Change in blood levels to assess efficacy of study drug
Week 5 (pre drug) to week 16 (post drug); approx. 8 week
Brain Natriuretic Protein
Tidsramme: Week 5 (pre drug) to week 16 (post drug); approx. 8 weeks
Change in brain natriuretic protein (BNP)
Week 5 (pre drug) to week 16 (post drug); approx. 8 weeks
Cardiopulmonary Exercise Testing: iCPET
Tidsramme: Week 3 (pre-drug) to week 10 (post drug); approx. 8 weeks
Invasive cardiopulmonary exercise testing
Week 3 (pre-drug) to week 10 (post drug); approx. 8 weeks
Cardiopulmonary Exercise Testing; nCPET
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Non-invasive cardiopulmonary exercise testing
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Cognitive Function
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Change in pre and post scores on the Montreal Cognitive Assessment
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Co-morbid Illness
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Change in pre and post scores on the Charlson Comorbidity Index
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Co-morbidity Medications
Tidsramme: Week 1 pre drug to week 16 post drug
Medications for comorbidity managment
Week 1 pre drug to week 16 post drug
Echocardiogram
Tidsramme: Week 1 pre-drug to week 16 post drug
Change in cardiac strain
Week 1 pre-drug to week 16 post drug
Fatigability
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Change in pre and post scores on the Pittsburgh Fatigability Index
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Frailty Index Assessment
Tidsramme: Week 1 screening pre-drug to week 16 post drug
Physician assessment of frailty using the Canadian Clinical Frailty Scale
Week 1 screening pre-drug to week 16 post drug
Gene Expression
Tidsramme: Week 5 (pre drug) to week 16 (post drug); approx. 8 week
Change in DNA from Polymerase Chain Reaction analysis
Week 5 (pre drug) to week 16 (post drug); approx. 8 week
Glomerular Filtration Rate
Tidsramme: Week 5 (pre drug) to week 16 (post drug); approx. 8 week
Change in glomerular filtration rate (GFR)
Week 5 (pre drug) to week 16 (post drug); approx. 8 week
Glycosylated Hemoglobin
Tidsramme: Week 5 (pre drug) to week 16 (post drug); approx. 8 week
Change in glycosylated hemoglobin (HgbA1c)
Week 5 (pre drug) to week 16 (post drug); approx. 8 week
Hematocrit
Tidsramme: Week 1 pre drug to week 16 post drug
Change in hematocrit
Week 1 pre drug to week 16 post drug
Hemoglobin
Tidsramme: Week 1 pre drug to week 16 post drug
Change in hemoglobin
Week 1 pre drug to week 16 post drug
Hemodynamics; Blood Pressure
Tidsramme: Week 1 pre drug to week 16 post drug
Change in Blood pressure
Week 1 pre drug to week 16 post drug
Hemodynamics; Heart Rate
Tidsramme: Week 1 pre drug to week 16 post drug
Change in heart rate
Week 1 pre drug to week 16 post drug
Muscle Protein
Tidsramme: Week 5 (pre drug) to week 16 (post drug); approx. 8 week
Change in protein content of muscle fiber
Week 5 (pre drug) to week 16 (post drug); approx. 8 week
Near Infrared Spectroscopy
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Assessment of blood flow during exercise
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Pain
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Change in pre and post scores on the McGill Pain Questionnaire
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Physical Frailty and Balance
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Change in score on Standard Physical Performance Battery at visit 2 pre drug and visit 5
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Physical Activity
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Change in pre and post scores on the CHAMPS (Community Healthy Activities Program for Seniors) Activities Questionnaire for Older Adults-physical activity
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Quality of Life
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Change in pre and post scores on the Kansas City Cardiomyopathy Questionnaire subject self reported responses
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Submaximal Exercise Performance
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Change in distance on six minute walk test
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Self-efficacy
Tidsramme: Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Change in pre and post scores on the Sullivan Cardiac Self Efficacy questionnaire
Week 2(pre drug) to Week 10( post drug); approx. 8 weeks
Thyroid Stimulating Hormone
Tidsramme: Week 5 (pre drug) to week 16 (post drug); approx. 8 weeks
Change in thyroid stimulating hormone (TSH)
Week 5 (pre drug) to week 16 (post drug); approx. 8 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Gladwin, Mark, MD

Samarbejdspartnere

National Institute on Aging (NIA)

Efterforskere

  • Ledende efterforsker: Daniel E Forman, MD, University of Pittsburgh

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. april 2017

Primær færdiggørelse (Faktiske)

2. december 2018

Studieafslutning (Faktiske)

31. december 2018

Datoer for studieregistrering

Først indsendt

13. september 2016

Først indsendt, der opfyldte QC-kriterier

28. september 2016

Først opslået (Skøn)

29. september 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. januar 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. januar 2020

Sidst verificeret

1. januar 2020

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • STUDY19070450
  • 1R56AG051637-01A1 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Ja

IPD-planbeskrivelse

De-identified data may be shared with other future investigators as research questions arise.

IPD-delingstidsramme

A limit in time frame for sharing has not been defined.

IPD-delingsadgangskriterier

Only de-identified data approved for sharing by the PI.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Hjertefejl

Kliniske forsøg med sodium nitrite

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Brazil

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner